Cumberland pharmaceuticals partners with qureight to advance innovative idiopathic pulmonary fibrosis treatment research

Cumberland leveraging qureight's deep-learning ai platform  for its phase ii fighting fibrosis™ clinical trial nashville, tenn. and cambridge, england , may 13, 2025 /prnewswire/ -- cumberland pharmaceuticals inc. (nasdaq: cpix), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced a partnership with qureight, a core imaging laboratory developing deep-learning image analytics, to enhance the outcome and output of data from cumberland's fighting fibrosis™ clinical trial.
CPIX Ratings Summary
CPIX Quant Ranking